Experienced in Extracranial-Intracranial Bypass Surgery

Wei C. Wei

Holistic Medicine
345 9th St, Ste. 307, 
Oakland, CA 
Experienced in Extracranial-Intracranial Bypass Surgery
345 9th St, Ste. 307, 
Oakland, CA 
OverviewInsuranceLocationsClinical Research

Overview

Wei Wei is a Holistic Medicine provider in Oakland, California. Ms. Wei is rated as an Experienced provider by MediFind in Extracranial-Intracranial Bypass Surgery. Her top areas of expertise are Periodontitis, Menopause, Paroxysmal Supraventricular Tachycardia (PSVT), Endoscopy, and Hepatectomy.

Her clinical research consists of co-authoring 6546 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Extracranial-Intracranial Bypass Surgery.

Specialties
Holistic Medicine
Licenses
Acupuncturist in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

345 9th St, Ste. 307, Oakland, CA 94607

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 1 Less Clinical Trial

6543 Total Publications

Photoinduced EDA complex triggered difluoroalkylation of quinoxalin-2(1H)-ones with unactivated alkenes and fluoroalkyl bromides.
Photoinduced EDA complex triggered difluoroalkylation of quinoxalin-2(1H)-ones with unactivated alkenes and fluoroalkyl bromides.
Journal: Chemical communications (Cambridge, England)
Published: October 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Wei's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 59 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile